Show simple item record

dc.contributor.authorKaur, Namrita
dc.contributor.authorGuan, Yingshu
dc.contributor.authorRaja, Rida
dc.contributor.authorRuiz-Velasco, Andrea
dc.contributor.authorLiu, Wei; email: wei.liu@manchester.ac.uk
dc.date.accessioned2021-07-05T07:05:39Z
dc.date.available2021-07-05T07:05:39Z
dc.date.issued2021-06-21
dc.date.submitted2021-04-13
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625142/fphys-12-694864.pdf?sequence=2
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625142/additional-files.zip?sequence=3
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/625142/fphys-12-694864.xml?sequence=4
dc.identifier.citationFrontiers in Physiology, volume 12, page 694864
dc.identifier.urihttp://hdl.handle.net/10034/625142
dc.descriptionFrom Frontiers via Jisc Publications Router
dc.descriptionHistory: collection 2021, received 2021-04-13, accepted 2021-05-10, epub 2021-06-21
dc.descriptionPublication status: Published
dc.description.abstractThe incidence of heart failure (HF) continues to increase rapidly in patients with diabetes. It is marked by myocardial remodeling, including fibrosis, hypertrophy, and cell death, leading to diastolic dysfunction with or without systolic dysfunction. Diabetic cardiomyopathy (DCM) is a distinct myocardial disease in the absence of coronary artery disease. DCM is partially induced by chronic systemic inflammation, underpinned by a hostile environment due to hyperglycemia, hyperlipidemia, hyperinsulinemia, and insulin resistance. The detrimental role of leukocytes, cytokines, and chemokines is evident in the diabetic heart, yet the precise role of inflammation as a cause or consequence of DCM remains incompletely understood. Here, we provide a concise review of the inflammatory signaling mechanisms contributing to the clinical complications of diabetes-associated HF. Overall, the impact of inflammation on the onset and development of DCM suggests the potential benefits of targeting inflammatory cascades to prevent DCM. This review is tailored to outline the known effects of the current anti-diabetic drugs, anti-inflammatory therapies, and natural compounds on inflammation, which mitigate HF progression in diabetic populations.
dc.languageen
dc.publisherFrontiers Media S.A.
dc.rightsLicence for this article: http://creativecommons.org/licenses/by/4.0/
dc.sourceeissn: 1664-042X
dc.subjectPhysiology
dc.subjectdiabetes mellitus
dc.subjectinflammation
dc.subjectdiabetic cardiomyopathy
dc.subjecttreatment
dc.subjectheart failure
dc.titleMechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response
dc.typearticle
dc.date.updated2021-07-05T07:05:38Z
dc.date.accepted2021-05-10


Files in this item

Thumbnail
Name:
fphys-12-694864.pdf
Size:
698.5Kb
Format:
PDF
Thumbnail
Name:
additional-files.zip
Size:
412.2Kb
Format:
Unknown
Thumbnail
Name:
fphys-12-694864.xml
Size:
162.7Kb
Format:
XML

This item appears in the following Collection(s)

Show simple item record